Lured by China’s stunning economic growth and its rapidly burgeoning middle and upper classes – and under increasing pressure from the Chinese government to set up operations there - multinational pharmaceutical companies are increasingly drawn to this potent new market.

There is little doubt that China offers bountiful - and tempting - opportunities for pharmaceutical companies. Much of this appeal lies in its astounding economic growth along with its openness to clinical trials, and tremendous cost savings in research & development. For all its opportunities, however, China also poses a unique set of challenges for pharmaceutical companies, including intellectual property, complex distribution channels and pricing.

Learn more about Deloitte member firms' point of view on how life sciences companies should approach the opportunities and challenges of the China market from the attached article.